Metoprolol has a good impact on improving symptoms and quality of life in obstructive hypertrophic cardiomyopathy.
A TEMPO study found that metoprolol for 2 weeks improved left ventricular outflow gradient, symptoms, and quality of life compared to placebo in patients with obstructive hypertrophic cardiomyopathy. 8220; The action of (beta-blockers) is mediated by sympathetic modulation, with a decrease in heart rate and ventricular contractility, to prolong ventricular relaxation and diastolic filling, thereby reducing left ventricular outflow tract obstruction. For decades, the main treatment for patients with symptomatic left ventricular outflow tract obstruction has been moderate non-vasodilation (beta-blockers) at the maximum tolerated dose. However, the number of randomized, double-blind, placebo-controlled trials evaluating the effectiveness of (beta-blockers) is limited.

The use of β-adrenergic blockers in patients with symptoms of obstructive hypertrophic cardiomyopathy (HCM) is based on clinical experience and observational cohort studies.
target
This study aimed to investigate the effects of metoprolol on left ventricular outflow tract occlusion (LVOT), symptoms and motor performance in patients with obstructive HCM.

Beta-blocker (BB) therapy has been used for decades to relieve symptoms in people with obstructive hypertrophic cardiomyopathy (HCM).
However, recommendations for the use of explosives are based on expert opinion and observational cohort studies.
Target. The purpose of this study was to investigate the effects of metoprolol on left ventricular outflow tract occlusion (LVOT), symptoms and motor performance in patients with obstructive HCM.
patients received either metoprolol or placebo for 2 consecutive weeks in a randomized sequence.
Similarly, none of the patients achieved a CCS ≥ III while receiving metoprolol compared to 10% of the placebo group (p & lt; 0.01).
Maximum oxygen consumption did not differ between study groups. A
TEMPO study found that metoprolol succinate reduced LVOT obstruction, relieving symptoms, and improved quality of life.

This study observed Lopressor succinate versus placebo in patients with a hypertrophic hindering heart condition (HOCM).
organization Patients with parallel crossover HOCM mistreatment placebo were randomised to receive metoprolol succinate (n = 29) versus placebo (n = 29) for two weeks, then switched to the other treatment at intervals 2 weeks.
Interpretation:
the utilization of metoprolol succinate in symptomatic patients with HOCM has been beneficial. Lopressor succinate was related to a lower LVOT slope, improvement in symptoms and quality of life compared to placebo. Lopressor succinate didn’t improve exercise tolerance. effects with Lopressor succinate. Beta-blockers have long been thought about as the first-line treatment for HOCM. However, just some studies have studied this practice.